Does BRAF V600E mutation change the treatment in craniopharyngioma?
International Journal of Neurooncology · 2019
DOI: 10.4103/ijno.ijno_11_19 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Neurooncology, 2019. Verfasst von YaseminBenderli Cihan. Die Arbeit nennt 9 Literaturangaben.
Abstract (Originalsprache)
Sir, Craniopharyngiomas (CGs) are rare, benign, epithelial tumors located in the sellar/suprasellar region originating from the epithelial residues of the Rathke sac. They constitute 2%–5% of all intracranial tumors and 6%–13% of childhood tumors. Although they can be seen at any age, they show epidemiological bimodal age distribution. The first peak is between the ages of 5 and 14, and the second peak is between the ages of 50 and 74. They become a fairly large mass before becoming symptomatic due to their slow growth. They usually present with endocrine dysfunctions and visual disturbances. Headache is the most common complaint in CGs’ clinic.[1‐3] Pathologically, there are two subtypes, adamantinomatous and solid papillary. Papillary CG is generally seen in adults, but it is seen in pediatric age group. CGs are pathologically heterogeneous as well as radiologically they do not constitute a standard view. They can be completely cystic, completely solid, or both cystic and solid. Computed tomography, magnetic resonance imaging, and cerebral angiography are the main investigations. The treatment is planned according to the patient with a multidisciplinary approach. Treatment modalities include surgery, chemotherapy, and radiotherapy. Surgical gold is the standard treatment in CGs, and the aim is to perform a total gross resection with minimal morbidity. In the case of large‐volume tumors, small age, and recurrent hydrocephalus, relapse is more common, whereas total resection and recurrence after subtotal resection are less frequent in radiotherapy. Despite total excision of the tumor, recurrence ranges between 5% and 30%. However, when the literature is examined, it is seen that there is no growth in residual tumors or the tumor recurred after total removal of tumor. The cause of recurrence and the recurrence of which tumor is not strictly determined. The most common cause is the total absence of tumor. In case of relapse, surgical treatment and/or radiotherapy is applied.[1‐4]
Zitieren
APA
Cihan, Y. (2019). Does BRAF V600E mutation change the treatment in craniopharyngioma?. International Journal of Neurooncology. https://doi.org/10.4103/ijno.ijno_11_19
Vancouver
Cihan Y. Does BRAF V600E mutation change the treatment in craniopharyngioma?. International Journal of Neurooncology. 2019. doi:10.4103/ijno.ijno_11_19
BibTeX
@article{Cihan2019,
author = {Cihan, YaseminBenderli},
title = {Does BRAF V600E mutation change the treatment in craniopharyngioma?},
journal = {International Journal of Neurooncology},
year = {2019},
doi = {10.4103/ijno.ijno_11_19}
}
EUVIMED